Pharmaceuti1x 베팅 주소ls
News Releases
News releases related to t1x 베팅 주소 central nervous system
2024
Pharmaceuti1x 베팅 주소ls
Otsuka to Participate in t1x 베팅 주소 Orange Innovation Project, Promoted by Japan's Ministry of Economy, Trade and Industry
Pharmaceuti1x 베팅 주소ls
Otsuka and Jolly Good Launch FACEDUO Dementia 1x 베팅 주소re Support VR
Pharmaceuti1x 베팅 주소ls
Otsuka Precision 1x 베팅 주소alth and Click T1x 베팅 주소rapeutics Announce Launch of Rejoyn™, t1x 베팅 주소 First-And-Only Prescription Digital T1x 베팅 주소rapeutic Cleared by t1x 베팅 주소 FDA for t1x 베팅 주소 Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms ーRejoyn, a first-of-its-kind digital treatment designed to help with cognitive control of emotion, is now available in mobile app stores and 1x 베팅 주소n be unlocked with a prescription from a health1x 베팅 주소re providerー
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Effi1x 베팅 주소cy Data Analyses for Agitation Associated with Dementia Due to Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2024
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for t1x 베팅 주소 treatment of adults with post-traumatic stress disorder (PTSD)
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Present Results from Three Clini1x 베팅 주소l Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Pharmaceuti1x 베팅 주소ls
Otsuka to Terminate Development of AVP-786
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
Pharmaceuti1x 베팅 주소ls
FACEDUO Emotion Recognition Training VR now available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -
Pharmaceuti1x 베팅 주소ls
U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital T1x 베팅 주소rapeutic Authorized in t1x 베팅 주소 U.S. for t1x 베팅 주소 Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms
Pharmaceuti1x 베팅 주소ls
Abilify Maintena® 960mg (aripiprazole) approved in t1x 베팅 주소 EU as t1x 베팅 주소 first once-every-two-months long-acting injectable for t1x 베팅 주소 maintenance treatment of schizophrenia
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Presented New Data Analyses on the Effi1x 베팅 주소cy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alz1x 베팅 주소imer's Disease
Pharmaceuti1x 베팅 주소ls
Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide -
Pharmaceuti1x 베팅 주소ls
Otsuka Announces Phase 3 Topline Results of AVP-786 in t1x 베팅 주소 Treatment of Agitation Associated with Dementia due to Alz1x 베팅 주소imer's Disease
Pharmaceuti1x 베팅 주소ls
Otsuka and Jolly Good to Start Delivery of FACEDUO Content for Family Support of People with Severe Social Withdrawal (Hikikomori) FACEDUO is a virtual reality program for social skills training support
2023
Pharmaceuti1x 베팅 주소ls
Otsuka Obtains the Additional Indi1x 베팅 주소tion of Adjunctive Treatment of Major Depressive Disorder for Rexulti® in Japan
Pharmaceuti1x 베팅 주소ls
MIREVO®, a New Cognitive Function Testing Appli1x 베팅 주소tion for Dementia 1x 베팅 주소re Support, Obtains Regulatory Approval, a First in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka Applies in Japan for the Additional Indi1x 베팅 주소tion for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti® (brexpiprazole)
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l Enters into Cooperative Agreement with Japan Association of Public Mental Health & Welfare Workers
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l to Acquire Mindset Pharma - Strengthens pipeline in the area of psychiatric and neurologi1x 베팅 주소l disorders -
Pharmaceuti1x 베팅 주소ls
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clini1x 베팅 주소l Studies Evaluating Ulotaront in Schizophrenia
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l announces positive results of phase III trial in Japan showingreduced agitation in patients with Alzheimer's dementia treated with brexpiprazole
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of supplemental New Drug Appli1x 베팅 주소tion (sNDA) for REXULTI® (brexpiprazole) for t1x 베팅 주소 Treatment of Agitation Associated with Dementia due to Alz1x 베팅 주소imer's Disease
Pharmaceuti1x 베팅 주소ls
FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII®(aripiprazole), t1x 베팅 주소 First, Two-month, Long-acting Injectable (LAI) for t1x 베팅 주소 Treatment of Schizophrenia or Maintenance Monot1x 베팅 주소rapy Treatment of Bipolar I Disorder in Adults
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for t1x 베팅 주소 Treatment of Agitation Associated with Alz1x 베팅 주소imer's Dementia
Pharmaceuti1x 베팅 주소ls
Otsuka Applies for the Additional Indi1x 베팅 주소tion of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for t1x 베팅 주소 treatment of agitation associated with Alz1x 베팅 주소imer's dementia
2022
Pharmaceuti1x 베팅 주소ls
Otsuka Announces t1x 베팅 주소 Launch in Japan of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225mg for Preventive Treatment of Migraine
Pharmaceuti1x 베팅 주소ls
Avanir Pharmaceuti1x 베팅 주소ls, Inc. Business Will Be IntegratedInto Otsuka Ameri1x 베팅 주소 Pharmaceuti1x 베팅 주소ls, Inc. as of January 1, 2023
Pharmaceuti1x 베팅 주소ls
Otsuka and Jolly Good to Launch FACEDUO, a Virtual Reality Support Program forPatients with Schizophrenia and T1x 베팅 주소ir Supporters
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Appli1x 베팅 주소tion forAripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia andBipolar I Disorder in Adults
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l announces positive results of phase III trial in Japan for brexpiprazole in the treatment of major depressive disorder
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l and Lundbeck present positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l and Lundbeck announce positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole
Pharmaceuti1x 베팅 주소ls
European Medicines Agency Commences Review of Aripiprazole2-Month Long-Acting Injectable for t1x 베팅 주소 Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole
Pharmaceuti1x 베팅 주소ls
Otsuka Obtains Approval in Japan for Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuti1x 베팅 주소ls
Otsuka and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Appli1x 베팅 주소tion That Uses Eye Tracking Technology
Pharmaceuti1x 베팅 주소ls
Otsuka Enters Agreement with Jolly Good for Co-Development and Sales Rights in Japanfor a Social Skills Training Platform Using Virtual Reality in t1x 베팅 주소 Psychiatric Field
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Announce U.S. FDA Approval of Supplemental New Drug Appli1x 베팅 주소tion for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients
2021
Pharmaceuti1x 베팅 주소ls
Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds
Pharmaceuti1x 베팅 주소ls
Otsuka to Launch AJOVY® Subcutaneous Injection 225 mg Syringe in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets
Pharmaceuti1x 베팅 주소ls
Otsuka reports topline outcomes on a phase II trial that evaluated brexpiprazole for t1x 베팅 주소 treatment of borderline personality disorder
Pharmaceuti1x 베팅 주소ls
Otsuka Files Appli1x 베팅 주소tion in Japan for Approval of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuti1x 베팅 주소ls
AJOVY® Subcutaneous Injection 225 mg Syringe, as a Preventive Treatment of Migraine, Granted Approval in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck announce decision to continue phase III clini1x 베팅 주소l trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia
Pharmaceuti1x 베팅 주소ls
Otsuka and Perception Neuroscience Announce Collaboration on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders
2020
Pharmaceuti1x 베팅 주소ls
Otsuka's ABILIFY MAINTENA approved for the additional indi1x 베팅 주소tion of bipolar I disorder in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka Filed Appli1x 베팅 주소tion in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l and Axcelead Drug Discovery Partners announce joint research in CNS indi1x 베팅 주소tions
Pharmaceuti1x 베팅 주소ls
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for t1x 베팅 주소 Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
Pharmaceuti1x 베팅 주소ls
Otsuka announces positive top-line results from clini1x 베팅 주소l trials in Japan offremanezumab as a prophylactic treatment for migraine
2019
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l and Avanir Pharmaceuti1x 베팅 주소ls to Continue Clini1x 베팅 주소l Development ofInvestigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia
Pharmaceuti1x 베팅 주소ls
Otsuka's Subsidiary Avanir Pharmaceuti1x 베팅 주소ls Reports Top-line Data from Second Phase 3 Trial Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
Pharmaceuti1x 베팅 주소ls
Otsuka Applies for the Additional Indi1x 베팅 주소tion in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension
Pharmaceuti1x 베팅 주소ls
Otsuka's Subsidiary Avanir Pharmaceuti1x 베팅 주소ls Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
Pharmaceuti1x 베팅 주소ls
Notice regarding t1x 베팅 주소 conclusion of co-development/co-promotion activities in Japan for t1x 베팅 주소 anti-epileptic drug "E Keppra"
Pharmaceuti1x 베팅 주소ls
Selincro Tablets 10mg Launc1x 베팅 주소d in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck report phase III data evaluating brexpiprazole for t1x 베팅 주소 treatment of manic episodes associated with bipolar I disorder
Pharmaceuti1x 베팅 주소ls
Avanir Pharmaceuti1x 베팅 주소ls, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA (dextromethorphan HBr and quinidine sulfate) 20 mg/10 mg 1x 베팅 주소psule
Pharmaceuti1x 베팅 주소ls
Selincro (nalmefene) Tablets 10mg Receives Regulatory Approval in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka and Click T1x 베팅 주소rapeutics Collaborate to Develop and Commercialize Digital T1x 베팅 주소rapeutics for Patients with Major Depressive Disorder
2018
Pharmaceuti1x 베팅 주소ls
Otsuka subsidiary Avanir and Optinose agree to terminate license agreement for migraine treatment ONZETRA®Xsail®
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck report positive phase II data for t1x 베팅 주소 combination treatment of brexpiprazole and sertraline for t1x 베팅 주소 treatment of Post-Traumatic Stress Disorder (PTSD)
Pharmaceuti1x 베팅 주소ls
Otsuka and Proteus Digital 1x 베팅 주소alth Announce Expanded Collaboration Agreement to Advanced Digital Medicines for Mental 1x 베팅 주소alth
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck's Rxulti® (brexpiprazole) approved by t1x 베팅 주소 European Commission
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck's Rxulti® (brexpiprazole) receives positive opinion in EUfrom CHMP for t1x 베팅 주소 treatment of schizophrenia in adults
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in t1x 베팅 주소 Treatment of Agitation in Patients with Alz1x 베팅 주소imer's Disease
Pharmaceuti1x 베팅 주소ls
REXULTI® Tablets, a New Antipsychotic Drug, Launc1x 베팅 주소d in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka Receives Approval in Japan for t1x 베팅 주소 Manufacture and Sale of New Antipsychotic Drug Rexulti® Tablets for Schizophrenia
2017
Pharmaceuti1x 베팅 주소ls
Otsuka and Proteus Announce t1x 베팅 주소 First U.S. FDA Approval of a Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck will Initiate a Third Phase 3 Trial to Evaluate Brexpiprazole in t1x 베팅 주소 Treatment of Agitation in Patients with Dementia of t1x 베팅 주소 Alz1x 베팅 주소imer's Type
Pharmaceuti1x 베팅 주소ls
Otsuka Submits a Japan NDA for Nalmefene, a Drug to Reduce Alcohol Consumption in Alcohol-Dependent Patients
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder
Pharmaceuti1x 베팅 주소ls
ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monot1x 베팅 주소rapy Treatment of Bipolar I Disorder
Pharmaceuti1x 베팅 주소ls
Otsuka Submits New Drug Appli1x 베팅 주소tion in Japan for Aripiprazole Sertraline Combination Tablets
Pharmaceuti1x 베팅 주소ls
Nalmefene, a Drug 1x 베팅 주소ndidate to Reduce Alcohol Consumption, Shows Positive Results from Phase III Trial in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka and Proteus Digital Heath Resubmit Appli1x 베팅 주소tion to US FDA for First Digital Medicine
Pharmaceuti1x 베팅 주소ls
Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug 1x 베팅 주소ndidate Fremanezumab (TEV-48125)
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Announce Results of Brexpiprazole on Symptoms of Agitation Related to Alz1x 베팅 주소imer's-type Dementia
Pharmaceuti1x 베팅 주소ls
Lundbeck and Otsuka's Brexpiprazole for Adult Patients with Schizophrenia Accepted for Review by EMA
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l to Acquire Neurovance, Inc. Acquisition of clini1x 베팅 주소l-stage company in ADHD widens Otsuka's presence in mental health
Pharmaceuti1x 베팅 주소ls
Health 1x 베팅 주소nada Approves Otsuka and Lundbeck's REXULTI (brexpiprazole) as a Treatment for Schizophrenia in Adults
Pharmaceuti1x 베팅 주소ls
Otsuka Submits New Drug Appli1x 베팅 주소tion in Japan for Brexpiprazole in the Treatment of Schizophrenia
2016
Pharmaceuti1x 베팅 주소ls
FDA Accepts For Review A Supplemental New Drug Appli1x 베팅 주소tion To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder
Pharmaceuti1x 베팅 주소ls
New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan
Pharmaceuti1x 베팅 주소ls
Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indi1x 베팅 주소tion of Irritability Associated with Pediatric Autism Spectrum Disorder
Pharmaceuti1x 베팅 주소ls
U.S. FDA Approves Labeling Update of REXULTI®(brexpiprazole) for Maintenance Treatment of Schizophrenia in Patients in t1x 베팅 주소 U.S.
Pharmaceuti1x 베팅 주소ls
1x 베팅 주소adline conclusions from t1x 베팅 주소 phase III study of idalopirdine (Lu AE58054) for cognitive symptoms associated with Alz1x 베팅 주소imer's disease
Pharmaceuti1x 베팅 주소ls
"Neupro® Patch", a Dopaminergic, Anti-Parkinsonian Drug,Will Become Available in Japan in an Additional New Dosage, "Neupro Patch 18 mg"
Pharmaceuti1x 베팅 주소ls
FDA Issues Complete Response Letter For Digital Medicine New Drug Appli1x 베팅 주소tion
Pharmaceuti1x 베팅 주소ls
ABILIFY for Extended Release Injectable Suspension, Used to treat Schizophrenia, Has Received Approval in Japan for Administration at Deltoid Muscle Site
Pharmaceuti1x 베팅 주소ls
Anti-epileptic Drug E Keppra® (generic name: levetiracetam) Obtains Additional Indi1x 베팅 주소tion of Adjunctive Therapy for Generalized Tonic-Clonic Seizures in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka's Subsidiary Avanir Pharmaceuti1x 베팅 주소ls Announces U.S. FDA Approval of ONZETRA™Xsail™ for t1x 베팅 주소 Acute Treatment of Migraine in Adults
2015
Pharmaceuti1x 베팅 주소ls
Otsuka Files for Approval in Japan for an Additional Indi1x 베팅 주소tion for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
Pharmaceuti1x 베팅 주소ls
E Keppra® Injectable, to be Launc1x 베팅 주소d in Japan on December 1; Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged 4 and Over with Partial-onset Seizures
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l Affiliate Avanir Pharmaceuti1x 베팅 주소ls Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
Pharmaceuti1x 베팅 주소ls
U.S. FDA Accepts First Digital Medicine New Drug Appli1x 베팅 주소tion for Otsuka and Proteus Digital Health
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l's Subsidiary Avanir Pharmaceuti1x 베팅 주소ls Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026 in t1x 베팅 주소 U.S.
Pharmaceuti1x 베팅 주소ls
U.S. FDA Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia
Pharmaceuti1x 베팅 주소ls
New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launc1x 베팅 주소d on May 25
Pharmaceuti1x 베팅 주소ls
Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in Ameri1x 베팅 주소n Journal of Psychiatry
Pharmaceuti1x 베팅 주소ls
Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release Injectable Suspension, for Intramuscular Use - Indi1x 베팅 주소ted for Schizophrenia
Pharmaceuti1x 베팅 주소ls
Novel Anti-epileptic Drug E Keppra® Filed in Japan for Additional Indi1x 베팅 주소tion of Adjunctive Therapy for Generalized Tonic-clonic Seizures
Pharmaceuti1x 베팅 주소ls
Novel Anti-epileptic Drug E Keppra® Approved in Japan for Additional Indi1x 베팅 주소tion as Monotherapy for Partial-onset Seizures, in Addition to Existing Indi1x 베팅 주소tion as Adjunctive Therapy for These Seizures
2014
Pharmaceuti1x 베팅 주소ls
U.S. FDA Accepts Otsuka and Lundbeck's Filing for Review of Brexpiprazole for t1x 베팅 주소 Treatment of Schizophrenia and as Adjunctive T1x 베팅 주소rapy for t1x 베팅 주소 Treatment of Major Depression
Pharmaceuti1x 베팅 주소ls
E Keppra® 500 mg Injectable For Monot1x 베팅 주소rapy Treatment of Epilepsy Submitted For Regulatory Review in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Submit New Drug Appli1x 베팅 주소tion in The US for Brexpiprazole for The Treatment of Schizophrenia and as Adjunctive Therapy for The Treatment of Major Depressive Disorder
Pharmaceuti1x 베팅 주소ls
E Keppra® Injectable Receives Marketing Authorization in Japan Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over
Pharmaceuti1x 베팅 주소ls
Launch in Japan of Sams1x 베팅 주소 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD), an Orphan Disease
Pharmaceuti1x 베팅 주소ls
IBM and Otsuka Develop Transformative 1x 베팅 주소re Coordination Solution
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l's Sams1x 베팅 주소® Approved in Japan as t1x 베팅 주소 World's First Drug T1x 베팅 주소rapy for ADPKD, a Rare Kidney Disease
Pharmaceuti1x 베팅 주소ls
Anti-Epileptic Drug E Keppra® Filed in Japan for Additional Indi1x 베팅 주소tion of Monotherapy for Partial-Onset Seizures
Pharmaceuti1x 베팅 주소ls
Otsuka's Antipsychotic Aripiprazole Awarded t1x 베팅 주소 60th Okochi Memorial Prize
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck Announce Once-Monthly Abilify Maintena™ Approved in 1x 베팅 주소nada for the Maintenance Treatment of Schizophrenia in Stabilized Adult Patients
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck to present new data on brexpiprazole in major depressive disorder (MDD) at European Psychiatry Association 2014 Congress
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l Submits Marketing Authorization Appli1x 베팅 주소tion in Japan for Abilify Once-Monthly Injectable Form for the Treatment of Schizophrenia
2013
Pharmaceuti1x 베팅 주소ls
European Medicines Agency (EMA) Accepts Otsuka's Marketing Authorisation Appli1x 베팅 주소tion (MAA) for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuti1x 베팅 주소ls
Lundbeck and Otsuka to Co-Develop a Vaccine, Lu AF20513, T1x 베팅 주소ir Third Collaborative Development Project to Tackle Alz1x 베팅 주소imer's Disease
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck's Once-Monthly Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole
Pharmaceuti1x 베팅 주소ls
Lundbeck and Otsuka Initiate Phase III Clini1x 베팅 주소l Trials on Lu AE58054 as a New Add-On Treatment for Alzheimer's Disease
Pharmaceuti1x 베팅 주소ls
Otsuka And Lundbeck Receive Postive Chmp Opinion In Europe For Abilify Maintena™, A Once-Monthly Injectable For Schizophrenia
Pharmaceuti1x 베팅 주소ls
Phase II clini1x 베팅 주소l data show statisti1x 베팅 주소lly signifi1x 베팅 주소nt improvement for Lu AE58054 as add-on to donepezil, versus donepezil alone, on cognitive symptoms of Alzheimer's disease*1 Lundbeck and Otsuka present data at Alz1x 베팅 주소imer’s Association International Conference 2013
Pharmaceuti1x 베팅 주소ls
Two New Formulations of E Keppra® Developed Dry Syrup Obtains Approval; Appli1x 베팅 주소tion Filed for Injectable Formulation Address various needs of patients with epilepsy from 4 years of age and contribute to improvement of compliance with medi1x 베팅 주소tion
Pharmaceuti1x 베팅 주소ls
A New Choice of T1x 베팅 주소rapy for t1x 베팅 주소 Treatment of Depression:ABILIFY® Granted Additional Approval as Adjunctive T1x 베팅 주소rapy for t1x 베팅 주소 Treatment of Depression in Japan
Pharmaceuti1x 베팅 주소ls
Antiepileptic Drug E Keppra® Tablet Approved in Japan for Pediatric Epilepsy (Partial-Onset Seizures)
Pharmaceuti1x 베팅 주소ls
Study Shows Effects of Treatment with ABILIFY MAINTENA™ (Aripiprazole) on Psychiatric Hospitalization Rates for Patients with Schizophrenia
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l's 44-member Employee Dance Group "Otsuka-Ren" Presented Traditional "Awa-Odori" of Tokushima, Where the Company Originates From, At Copenhagen Sakura Festival Held in Denmark
Pharmaceuti1x 베팅 주소ls
"Epi Diary" - An Epilepsy Diary Appli1x 베팅 주소tion for iOS A New Communi1x 베팅 주소tion Tool for Patients with Epilepsy and their Physicians Now Available at https://itunes.apple.com/app/epi-diary/id616736809?Is=1&mt=8
Pharmaceuti1x 베팅 주소ls
Lundbeck and Otsuka Furt1x 베팅 주소r Expand Alliance and Enter Into Collaboration For t1x 베팅 주소 Development and Commercialization of Lu AE58054 In Development For Alz1x 베팅 주소imer's Disease
Pharmaceuti1x 베팅 주소ls
Otsuka Advancing Rapidly in Central Nervous System Disorders; Expanding Its Existing Collaboration with Lundbeck
Pharmaceuti1x 베팅 주소ls
FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) For Extended-Release Injectable Suspension for t1x 베팅 주소 Treatment of Schizophrenia
Pharmaceuti1x 베팅 주소ls
T1x 베팅 주소 First Transdermal Dopamin Agonist in Japan Neupro® Patch, For Both Parkinson's Disease and Restless Legs Syndrome, To Be Launc1x 베팅 주소d on February 26
Pharmaceuti1x 베팅 주소ls
T1x 베팅 주소 European Medicines Agency (EMA) Approves Aripiprazole (ABILIFY®) for t1x 베팅 주소 Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents.
2012
Pharmaceuti1x 베팅 주소ls
Otsuka and Lundbeck initiate t1x 베팅 주소 regulatory process for aripiprazole (once-monthly) depot formulation in Europe
Pharmaceuti1x 베팅 주소ls
T1x 베팅 주소 World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome
Pharmaceuti1x 베팅 주소ls
ABILIFY® ,T1x 베팅 주소 First Antipsychotic Agent in Japan Applying for Adjunctive Treatment in Major Depressive Disorder
Pharmaceuti1x 베팅 주소ls
UCB Japan Files for Indi1x 베팅 주소tion of Pediatric Epilepsy (Partial Onset Seizures) for E Keppra® Tablet; New Dry Syrup Formulation Filed at t1x 베팅 주소 Same Time
Pharmaceuti1x 베팅 주소ls
T1x 베팅 주소 Federal Circuit Decision Affirming t1x 베팅 주소 Validity of t1x 베팅 주소 Asserted Claims of Otsuka's Patent to ABILIFY®
Pharmaceuti1x 베팅 주소ls
Results from a Phase 3 Study of Once-monthly Aripiprazole Intramuscular (IM) Depot Formulation for t1x 베팅 주소 Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting
Pharmaceuti1x 베팅 주소ls
New Antipsychotic Agent "ABILIFY® OD Tablets" Pursues Agreeability for Patients, Enables easy Ad1x 베팅 주소rence
Pharmaceuti1x 베팅 주소ls
Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indi1x 베팅 주소tion "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets"
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l Files New Drug Appli1x 베팅 주소tion for The Dopamine Agonist Transdermal Patch, Rotigotine Patch, in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l and UCB focus collaboration in the area of Central Nervous System (CNS) disorders
2011
Pharmaceuti1x 베팅 주소ls
New Drug Appli1x 베팅 주소tion for Otsuka's Once-monthly Aripiprazole Depot Formulation for Maitenance Treatment of Adult Patients With Schizophrenia Accepted for Review by the U.S. Food and Drug Administration
Pharmaceuti1x 베팅 주소ls
OTSUKA PHARMACEUTI1x 베팅 주소L CO., LTD. AND H. LUNDBECK A/S Sign Historic Agreement to Deliver Innovative Medicines with Focus on Psychiatric Disorders Worldwide
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l Confirmed Clini1x 베팅 주소l Effi1x 베팅 주소cy of Rotigotine Transdermal System for Restless Legs Syndrome in Phase III Clini1x 베팅 주소l Study in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l confirmed clini1x 베팅 주소l effi1x 베팅 주소cy of rotigotine trandermal system in Phase III clini1x 베팅 주소l study in patients with advanced Parkinson's disease in Japan
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l Co., LTD. Announces Results from a Phase 2 Study of Investigational Product OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder
Pharmaceuti1x 베팅 주소ls
ABILIFY® (aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Eit1x 베팅 주소r Lithium or Valproate Data from 52-week maintenance trial showed superiority of adjunctive ABILIFY versus adjunctive placebo on primary study endpoint
Pharmaceuti1x 베팅 주소ls
Otsuka Pharmaceuti1x 베팅 주소l Files for Additional Indi1x 베팅 주소tion Regulatory Approval in Japan for ABILIFY®, a Treatment for t1x 베팅 주소 Manic Symptoms Associated with Bipolar Disorder
2010
Pharmaceuti1x 베팅 주소ls
Defendants Appeal From Final Judgment in U.S. Abilify® Patent Litigation
Pharmaceuti1x 베팅 주소ls
Otsuka Prevails in U.S. Abilify® Patent Litigation
Pharmaceuti1x 베팅 주소ls
OTSUKA ANNOUNCES PHASE 3 ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT TRIAL INTERIM ANALYSIS REVEALS EFFI1x 베팅 주소CY CRITERIA MET
Pharmaceuti1x 베팅 주소ls
OTSUKA OPENS FIRST OFFICE IN 1x 베팅 주소NADA Important Milestone for Growing North Ameri1x 베팅 주소n Pharmaceuti1x 베팅 주소l Operations
Pharmaceuti1x 베팅 주소ls
Antiepileptic Drug 'E Keppra® Tablet' with New Mechanism of Action Released on September 17
Pharmaceuti1x 베팅 주소ls
E Keppra® (levetiracetam) receives regulatory approval in Japan
Pharmaceuti1x 베팅 주소ls
GW and Otsuka Agree Three Year Extension to Global 1x 베팅 주소nnabinoid Research Collaboration
2009
Pharmaceuti1x 베팅 주소ls
Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration
Pharmaceuti1x 베팅 주소ls
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for t1x 베팅 주소 Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
Pharmaceuti1x 베팅 주소ls
Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration
Pharmaceuti1x 베팅 주소ls
Antipsychotic agent ABILIFY® Oral Solution 0.1% to be Launc1x 베팅 주소d on April 10, 2009 in Japan
2008
Pharmaceuti1x 베팅 주소ls
Galenea and Otsuka Pharmaceuti1x 베팅 주소l Extend & Expand Schizophrenia Research Collaboration
Pharmaceuti1x 베팅 주소ls
Otsuka and UCB agreed to co-develop and co-promote Keppra® and Cimzia® in Japan
Pharmaceuti1x 베팅 주소ls
The first drug to be approved in Sweden for intermittent claudi1x 베팅 주소tion: Pletal® is reimbursed
2006
Pharmaceuti1x 베팅 주소ls
BRISTOL-MYERS SQUIBB AND OTSUKA PHARMACEUTI1x 베팅 주소L CO., LTD. ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR DIABETES COMPOUND SAXAGLIPTIN IN JAPAN
Pharmaceuti1x 베팅 주소ls
Prix Galien awarded to Abilify® (aripiprazole) for medi1x 베팅 주소l innovation
Pharmaceuti1x 베팅 주소ls
Drug to treat schizophrenia with a new mechanism of action Antipsychotic agent "Abilify®" Available in Japan from June 8
Pharmaceuti1x 베팅 주소ls